See analyst estimates and all valuation multiples for Nutraceuticals & Cosmeceuticals
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $28.0B | 1.8x | 7.6x | |
| $19.0B | 16.5x | 50.9x | |
| $14.8B | 10.1x | 31.0x | |
| $10.3B | 3.1x | 7.5x | |
| $7.3B | 4.7x | 23.4x | |
| $6.8B | 8.9x | 32.9x | |
| $3.4B | 1.6x | 9.8x | |
| $3.2B | 2.3x | 8.5x | |
| $3.1B | 1.5x | 10.0x | |
| $2.8B | 7.7x | 17.6x | |
| $1.6B | n/a | n/a | |
| $1.3B | 4.6x | 9.1x | |
| $1.3B | 2.2x | 11.5x | |
| $1.2B | 1.1x | 4.6x | |
| $1.1B | 5.0x | 18.4x | |
| $1.1B | 8.1x | 30.7x | |
| $990M | 6.4x | 22.2x | |
| $958M | n/a | n/a | |
| $929M | 3.8x | 9.4x | |
| $779M | n/a | n/a | |
| $766M | 1.7x | 8.2x | |
| $639M | 14.9x | 42.7x | |
| $626M | 4.2x | 16.2x | |
| $610M | n/a | n/a | |
| $512M | n/a | n/a | |
| $488M | 3.9x | 25.4x | |
| $260M | n/a | n/a | |
| $220M | 2.7x | 15.6x | |
| $191M | 2.9x | n/a | |
| $127M | 2.0x | 11.6x | |
| $75.8M | n/a | n/a | |
| $67.3M | n/a | n/a | |
| $59.4M | 4.2x | 48.2x | |
| $49.8M | 1.4x | 5.0x | |
| $32.1M | n/a | n/a | |
| $17.1M | n/a | n/a | |
| $16.6M | 0.9x | -9.9x | |
| $10.0M | 8.8x | -1.0x | |
| $7.5M | n/a | n/a | |
| $6.0M | n/a | n/a | |
| $4.4M | n/a | n/a | |
| -$0.3M | n/a | n/a | |
| -$61.4M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Nutraceuticals & Cosmeceuticals